| Literature DB >> 28331302 |
Mauro Carone1, Michele Vitacca2, Mara Paneroni2, Paola Baiardi3, Antonio Spanevello4, Giorgio Bertolotti5.
Abstract
Entities:
Mesh:
Year: 2017 PMID: 28331302 PMCID: PMC5352150 DOI: 10.2147/COPD.S130991
Source DB: PubMed Journal: Int J Chron Obstruct Pulmon Dis ISSN: 1176-9106
Four clinical cases according to GOLD severity criteria of obstruction: stages 1–4
| Patient no | GOLD | BMI (kg/m2) | FEV1% predicted | FVC% predicted | TI | Drug therapy | Rehabilitation sessions number | LTOT T0 | PaO2 T0 |
|---|---|---|---|---|---|---|---|---|---|
| #1 | 1 | 39.7 | 87 | 67 | 65 | LAMA | 20 | No | 89 |
| #2 | 2 | 25.1 | 62 | 96 | 65 | LAMA-LABA | 21 | No | 62 |
| #3 | 3 | 25.7 | 45 | 105 | 43 | LAMA-LABA-ICS | 27 | No | 81 |
| #4 | 4 | 34.0 | 27 | 58 | 46 | LAMA-LABA-ICS | 30 | Yes | 77.1 |
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; TI, Tiffeneau-index (FVC/FEV1); LTOT, long-term oxygen therapy; T0, at baseline; PaO2, partial pressure of oxygen; PaCO2, partial pressure of carbon dioxide; pH, logarithm of the reciprocal of hydrogen ion concentration; FiO2, inspiratory fraction of oxygen; 6MWT, 6-minute walking test; BI-d, Barthel index-dyspnea; T1, at the end of the rehabilitation program; LAMA, long-acting muscarinic agent; LABA, long-acting β2 agonist; ICS, inhaled corticosteroid; GOLD, Global Initiative for chronic Obstructive Lung Disease.
Figure 1Mean score distribution of each Barthel dyspnea item measured at the baseline (black columns) and at the end (gray columns) of the rehabilitation program. Subjects were subdivided according to GOLD severity grade.
Abbreviations: BI-d, Barthel index-dyspnea; GOLD, Global Initiative for chronic Obstructive Lung Disease.